Abstract
According to one popular theory, hepatic encephalopathy (HE) is partly caused by an imbalance in plasma amino acid levels. The Fischer’s ratio between branched chain amino acids (BCAAs) and aromatic amino acids (AAAs) correlates with the degree of HE; the lower Fischer’s ratio, the higher the grade of HE. Extra-corporeal liver support systems, like MARS®-albumin dialysis (Molecular Adsorbents Recirculating System), can improve HE. The MARS® system uses a hyperosmolar albumin circuit to remove both water-soluble and albumin-bound substances. Plasma levels of neuroactive amino acids were analyzed in 82 consecutive patients with life-threatening liver failure admitted to our ICU. All patients fulfilled our indications for MARS treatment and most also fulfilled the criteria for liver transplantation (LTx). In patients with acute liver failure (ALF), as compared to those with acute decompensation of chronic liver failure (AcOChr), levels of leucine and isoleucine were significantly higher before MARS® treatment. In all patients, before MARS® treatment the higher the grade of HE grade the lower was the Fischer’s ratio and higher were the levels of inhibitory neuroactive amino acids. During MARS® treatments the Fischer’s ratio increased, and the grade of HE decreased. The increase in Fischer’s ratio was mainly due to the decrease in AAAs. The plasma levels of neuroactive amino acids, methionine, glutamine, glutamate, histidine and taurine decreased during MARS®-treatment. In this study MARS®-albumin dialysis had a favorable effect on the plasma amino acid profile of patients with HE.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albrecht J, Jones EA (1999) Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome. J Neurol Sci 170(2):138–146 Nov 30
Awad SS, Swaniker F, Magee J, Punch J, Bartlett RH (2001) Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery 130(2):354–362 Aug
Ben Abraham R, Szold O, Merhav H, Biderman P, Kidron A, Nakache R (2001) Rapid resolution of brain edema and improved cerebral perfusion pressure following the molecular adsorbent recycling system in acute liver failure patients. Transplant Proc 33(6):2897–2899 Sep
Bergeron M, Layrargues GP, Butterworth RF (1989) Aromatic and branched-chain amino acids in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Metab Brain Dis 4(3):169–176 Sep
Bergeron M, Swain MS, Reader TA, Grondin L, Butterworth RF (1990) Effect of ammonia on brain serotonin metabolism in relation to function in the portacaval shunted rat. J Neurochem 55(1):222–229 Jul
Brandsaeter B, Hockerstedt K, Friman S, Ericzon BG, Kirkegaard P, Isoniemi H (2002) Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation—12 years experience in the nordic countries. Liver Transpl 8(11):1055–1062 Nov
Butterworth RF (1996) Neuroactive amino acids in hepatic encephalopathy. Metab Brain Dis 11(2):165–173 Jun
Butterworth RF (2003) Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: potential for improvement following their removal by liver assist devices. Liver Int 23(Suppl 3):5–9
Carpenedo R, Mannaioni G, Moroni F (1998) Oxindole, a sedative tryptophan metabolite, accumulates in blood and brain of rats with acute hepatic failure. J Neurochem 70(5):1998–2003 May
Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB (1976) The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 80(1):77–91 Jul
Giguere JF, Butterworth RF (1984) Amino acid changes in regions of the CNS in relation to function in experimental portal-systemic encephalopathy. Neurochem Res 9(9):1309–1321 Sep
Higashi T (1982) Impaired metabolism of methionine in severe liver diseases. I. clinical and pathophysiological significance of elevated serum methionine levels. Gastroenterol Jpn 17(2):117–124 Apr
Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM (1997) International union of pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 49(3):253–278 Sep
Jalan R, Shawcross D, Davies N (2003) The molecular pathogenesis of hepatic encephalopathy. Int J Biochem Cell Biol 35(8):1175–1181 Aug
Koivusalo AM, Isoniemi H, Vakkuri A, Hockerstedt K, Nuutinen H (2002) Without liver transplantation paracetamol intoxication is often be lethal, in spite of N-acetylcysteine therapy. Duodecim 118(6):649–650
Koivusalo AM, Yildirim Y, Vakkuri A, Lindgren L, Hockerstedt K, Isoniemi H (2003) Experience with albumin dialysis in five patients with severe overdoses of paracetamol. Acta Anaesthesiol Scand 47(9):1145–1150 Oct
Lahdenpera A, Koivusalo AM, Vakkuri A, Hockerstedt K, Isoniemi H (2005) Value of albumin dialysis therapy in severe liver insufficiency. Transpl Int 17(11):717–723 Jan
Loock J, Mitzner SR, Peters E, Schmidt R, Stange J (2002) Amino acid dysbalance in liver failure is favourably influenced by recirculating albumin dialysis (MARS). Liver 22(Suppl 2):35–39
Lozeva V, Tuomisto L, Tarhanen J, Butterworth RF (2003) Increased concentrations of histamine and its metabolite, tele-methylhistamine and down-regulation of histamine H3 receptor sites in autopsied brain tissue from cirrhotic patients who died in hepatic coma. J Hepatol 39(4):522–527 Oct
Martinez-Hernandez A, Bell KP, Norenberg MD (1977) Glutamine synthetase: glial localization in brain. Science 195(4284):1356–1358 Mar 25
Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 6(3):277–886 May
Pardridge WM (1998) Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res 23(5):635–644 May
Rosen HM, Yoshimura N, Hodgman JM, Fischer JE (1977) Plasma amino acid patterns in hepatic encephalopathy of differing etiology. Gastroenterology 72(3):483–487 Mar
Schmidt LE, Svendsen LB, Sorensen VR, Hansen BA, Larsen FS (2001) Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl. 7(8):709–712 Aug
Schmidt LE, Tofteng F, Strauss GI, Larsen FS (2004) Effect of treatment with the molecular adsorbents recirculating system on arterial amino acid levels and cerebral amino acid metabolism in patients with hepatic encephalopathy. Scand J Gastroenterol 39(10):974–980 Oct
Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H (1999) Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 23(4):319–330 Apr
Toborek M, Kopieczna-Grzebieniak E, Drozdz M, Wieczorek M (1995) Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits. Atherosclerosis 115(2):217–224 Jun
Trevisani F, Bernardi M, Arienti V, Scrivano P, Mazziotti A, Cavallari A (1994) Early and late changes in fasting and absorptive plasma amino acids and ammonia after distal splenorenal shunt in cirrhosis. Hepatology 19(2):329–338 Feb
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koivusalo, AM., Teikari, T., Höckerstedt, K. et al. Albumin dialysis has a favorable effect on amino acid profile in hepatic encephalopathy. Metab Brain Dis 23, 387–398 (2008). https://doi.org/10.1007/s11011-008-9110-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-008-9110-9